Tolerability of hormonal treatments in acute hepatic porphyria patients
Internal Medicine Journal · 2026
DOI: 10.1111/imj.70532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2026. Verfasst von Andjela Arandjelovic und 2 weiteren Autor:innen. Beteiligte Einrichtung: Porphyria Expert Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Porphyrias, Hepatic, Hormone Replacement Therapy. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Acute hepatic porphyria (AHP) flares have been associated with female hormones and the use of hormonal treatments. Women with AHP are traditionally advised to avoid exogenous oestrogen and progesterone, limiting options for contraception and management of menorrhagia, dysmenorrhoea and menopausal symptoms. Evidence on specific hormonal therapies is limited; a 2003 study found that 25% of women with acute intermittent porphyria (AIP) experienced attacks with contraceptives containing progesterone, oestrogen or both.
Aim
To update the current understanding of the tolerability of hormonal treatments in women with AHP.
Methods
An anonymous questionnaire was distributed to women with AHP (acute intermittent porphyria, hereditary coproporphyria and variegate porphyria) via hospital records and a national patient support group, capturing prior hormonal therapy use and associated flares.
Results
Thirty responses were analysed; 23 participants had used hormonal therapies. Flares were most frequent in hereditary coproporphyria (66%) and less common in variegate porphyria and acute intermittent porphyria (~20%). No flares were reported with hormone replacement therapy, the progesterone‐only pill or progesterone implants. Flares occurred with combined oral contraceptives (46.6%) and progesterone‐containing intrauterine devices (28.5%), particularly drospirenone‐containing pills. Levonorgestrel‐based therapies, including the Mirena IUD, were better tolerated and often improved symptoms.
Conclusions
Although limited by sample size and retrospective design, this study provides clinically useful data on the tolerability of specific hormonal therapies in women with AHP, supporting personalised prescribing and patient counselling for contraception and symptom management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Porphyria Expert Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
ORCID-Profile: Andjela Arandjelovic, Gayle Ross
Zitieren
APA
Arandjelovic, A., Ross, C., & Ross, G. (2026). Tolerability of hormonal treatments in acute hepatic porphyria patients. Internal Medicine Journal. https://doi.org/10.1111/imj.70532
Vancouver
Arandjelovic A, Ross C, Ross G. Tolerability of hormonal treatments in acute hepatic porphyria patients. Internal Medicine Journal. 2026. doi:10.1111/imj.70532
BibTeX
@article{Arandjelovic2026,
author = {Arandjelovic, Andjela and Ross, Charlotte and Ross, Gayle},
title = {Tolerability of hormonal treatments in acute hepatic porphyria patients},
journal = {Internal Medicine Journal},
year = {2026},
doi = {10.1111/imj.70532}
}
EUVIMED